Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Plasma N-terminal Pro-B-Type Natriuretic Peptide (Nt-proBNP) Levels in Patients Presenting With Cardiac Arrhythmias to the Emergency Department: A Prospective Observational Study From India.

Cureus·2026
Same author

Methodological considerations in assessing postintervention fitness and quality of life in congenital heart disease.

Annals of pediatric cardiology·2026
Same author

Intraocular foreign bodies in the posterior segment: Clinical characteristics, management, and visual outcomes.

Chinese journal of traumatology = Zhonghua chuang shang za zhi·2026
Same author

Impact of magnesium on the clearance of lactate in critically sick patients with sepsis: Randomized clinical trial.

World journal of critical care medicine·2026
Same author

Clinical profile and outcomes of critically ill obstetric patients in the intensive care unit of a tertiary care center.

World journal of critical care medicine·2026
Same author

Oromandibular Limb Hypogenesis Syndrome Type IVB with Hypoglossia and Intraoral Band: A Case Report of a Rare Entity.

Journal of maxillofacial and oral surgery·2026

Related Experiment Video

Updated: Jun 7, 2025

Reprograming Model of Human Monocyte-derived Macrophages for In-vitro Assays
08:37

Reprograming Model of Human Monocyte-derived Macrophages for In-vitro Assays

Published on: April 18, 2025

265

Navigating the mutation maze: An oncogenic driver's guide to macrophage reprogramming.

Ziyi Li1, Ankur Sharma2

  • 1Translational Genomics Program, Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, NSW 2010, Australia.

Immunity
|November 13, 2024
PubMed
Summary

Diffuse midline gliomas (DMGs) with H3.3K27M mutations are rich in disease-associated myeloid cells (DAMs). Targeting these myeloid cells can restore a healthy state, reduce tumor infiltration, and improve survival in cancer.

More Related Videos

In Vitro Assay to Study Tumor-macrophage Interaction
08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

7.5K
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

27.2K

Related Experiment Videos

Last Updated: Jun 7, 2025

Reprograming Model of Human Monocyte-derived Macrophages for In-vitro Assays
08:37

Reprograming Model of Human Monocyte-derived Macrophages for In-vitro Assays

Published on: April 18, 2025

265
In Vitro Assay to Study Tumor-macrophage Interaction
08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

7.5K
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

27.2K

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • The interplay between oncogenic mutations and tumor location in shaping the tumor immune microenvironment remains unclear.
  • Diffuse midline gliomas (DMGs) are aggressive brain tumors often driven by H3.3K27M mutations.

Purpose of the Study:

  • To investigate the immune landscape of H3.3K27M-mutant DMGs.
  • To explore therapeutic strategies targeting myeloid cells in these tumors.

Main Methods:

  • Analysis of immune cell populations within DMG tumors.
  • Development and testing of myeloid-targeted therapeutic strategies.

Main Results:

  • H3.3K27M DMGs exhibit a significant enrichment of disease-associated myeloid cells (DAMs).
  • Myeloid-targeted interventions successfully reprogrammed DAMs towards a homeostatic state.
  • Treatment led to reduced myeloid cell infiltration and extended survival in preclinical models.

Conclusions:

  • Disease-associated myeloid cells are key components of the H3.3K27M DMG immune microenvironment.
  • Targeting DAMs represents a promising therapeutic avenue for improving outcomes in diffuse midline gliomas.